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A	milestone	in	drug	policy:	saving	the	lives	of	people
who	use	drugs	and	were	homeless	in	Dublin	during
the	COVID-19	pandemic
Dublin	has	outperformed	even	best-case	scenarios	for	COVID-19	mortality	among
homeless	and	drug-using	populations,	write	Austin	O’Carroll,	Tony	Duffin	and	John	Collins	(LSE).	When
government	policy	is	well	coordinated	and	underpinned	by	a	science-driven	and	fundamentally	pragmatic	approach,
lives	are	saved.
When	the	COVID-19	pandemic	reached	Dublin,	homeless	people	were	identified	as	a
particularly	vulnerable	group	due	to	their	morbidity	profile,	living	conditions	and	drug	use	behaviour.	At	the	outset	of
the	policy	response	there	was	a	very	clear	sense	of	what	client	groups	were	being	targeted:	people	who	are
homeless,	and	who	use	drugs	in	Dublin	city	centre,	an	area	with	the	highest	population	of	these	clients.	Very	early
on,	the	Health	Service	Executive	appointed	a	Clinical	Lead	for	the	COVID-19	Homeless	Response.	Accommodation
to	allow	isolation	of	positive	and	suspected	cases	was	rapidly	obtained,	and	staff	were	funded	by	the	HSE.
Homeless	clients	who	were	deemed	vulnerable	due	to	age	or	medical	condition	were	moved	to	single	occupancy
accommodation	so	that	they	could	be	shielded	from	infection.	In	addition,	homeless	accommodation	with	large
numbers	of	residents	saw	many	transferred	in	order	to	decrease	occupancy	levels	and	thereby	to	reduce	the	risk	of
spreading	COVID-19.	By	early	June:
•	over	750	clients	had	been	tested;
•	over	330	clients	had	been	placed	in	isolation;
•	over	500	people	had	been	placed	in	shielding,	of	whom	340	were	shielded	in	newly
obtained	units;
•	120	people	were	moved	from	high	occupancy	units	to	new	reduced-occupancy
accommodation;
•	all	rough	sleepers	were	offered	accommodation.
The	result	was	that	COVID-19	infection	and	mortality	rates	were	very	low	with	only	63	homeless	people	diagnosed.
There	was	only	one	COVID-19-related	death,	a	fraction	of	what	had	been	predicted).	The	expansion	of	housing
provision	was	an	unequivocal	success	in	limiting	the	direct	effects	of	COVID-19	transmission	and	infection.
Dublin,	2019.	Photo:	Jose	Luis	Vazquez	Hernandez	via	a	CC-BY-NC-SA	2.0	licence
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In	Dublin	there	are	two	main	routes	for	homeless	clients	to	access	Opioid	Substitution	Therapy	(OST).	First,	the
National	Drug	Treatment	Centre	(NDTC),	which	is	a	designated	OST	service	for	homeless	people	from	across
Ireland.	The	NDTC	is	based	in	Dublin	city	centre	and	is	the	largest	treatment	centre	in	the	Republic.	Prior	to	the
COVID-19	crisis	the	NDTC	had	about	550	clients,	with	methadone	being	dispensed	on	site.	Second,	GMQ	Medical,
which	was	established	as	a	primary	care	service	for	homeless	people	based	out	of	day	services.
Before	the	crisis,	GMQ	Medical	had	about	150	clients.	However,	there	was	a	cap	on	the	numbers	of
patients/hostels	it	could	recruit	and	NDTC	had	capacity	issues.	Due	to	the	large	increase	in	the	homeless
population	in	Ireland	since	the	2007	recession,	there	has	been	an
imbalance	between	numbers	applying	for	treatment	and	those	actually	being	transferred
to	the	community.	This	resulted	in	a	waiting	time	for	treatment	for	GMQ	Medical	of
between	12-14	weeks.
It	was	quickly	recognised	that	one	of	the	main	deterrents	to	individual	compliance	with
isolation	and	shielding	guidelines	was	substance	use,	particularly	heroin.	Immediately,	the	HSE	issued	national
contingency	guidelines	allowing	for	reduced	waiting	times	and	removal	of	caps	on	recruitment	to	treatment.	In
addition,	other	drug	treatment	clinics	agreed	to	take	on	homeless	patients	resident	in	hostels	in	their	catchment
areas.	Waiting	times	dropped	overnight	from	12-14	weeks	to	2-3	days.	An	inpatient	unit	for	rapid	initiation	on	to
OST	for	COVID-19	positive,	and	suspected,	patients	was	established.	Supervision	guidelines	were	amended	to
allow	members	of	the	NDTC	and	two	other	services	to	collect	clients’	OST	and	other	medication	and	deliver	it	at
intervals	dictated	by	the	client’s	risk	of	overdose.
In	Dublin,	62%	of	homeless	people	on	OST	also	misuse	street	benzodiazepines	(BZD).	Before	the	pandemic,	GMQ
Medical	offered	BZD	detoxes	based	on	the	national	protocol,	but	only	offered	BZD	maintenance	in	occasional
cases	where	previous	detoxes	had	failed	and	the	client	was	seen	to	be	at	high	risk	from	substance	misuse.	As
COVID-19	infections	started	to	rise	in	Dublin	and	clients	were	placed	in	Isolation	Units	and	Shielding	Units,	it	was
realised	that	those	with	high	dose	BZD	dependence	were	unlikely	to	remain	in	their	accommodation	so	increasing
their,	and	other	residents’,	risk	of	infection.	National	contingency	guidelines	emerged	recommending	that	patients	in
isolation	could	be	offered	up	to	30mg	daily	to	prevent	withdrawals	for	the	period	of	isolation	only.
At	the	homeless	health	sector’s	weekly	meetings,	it	was	noted	that	the	health	and	behaviour	of	clients	on
maintenance	had	seemed	to	improve	and	that	they	had	complied	with	the	isolation/shielding	recommendations.	As
a	result,	GMQ	Medical	decided	to	offer	BZD	maintenance	treatment	to	all	patients	on	OST	with	established	BZD
dependency.
Naloxone	is	an	opioid	antagonist	recommended	by	the	WHO	for	the	treatment	of	opioid
overdose.	In	Ireland	there	are	relatively	restrictive	pathways	for	accessing	Naloxone.	Recognising	the	increased
risk	of	overdose	during	the	COVID-19	crisis,	the	process	for	accessing	Naloxone	was	quickly	adapted	those	most	at
risk.	Naloxone	packs	were	taken	out	by	Ana	Liffey	Drug	Project	when	delivering	their	Needle	and	Syringe
Programme	(NSP).	A	person	engaging	with	the	outreach	NSP	was	assessed	by	Ana	Liffey	Drug	Project,	who
briefed	them	and/or	their	partner/companion	on	the	process	of	using	Naloxone	and	gave	them	the	drug.	The	names
and	date	of	birth	were	later	provided	to	a	GP	who	issued	the	prescription	for	Naloxone	retrospectively.
On	26	March	2020,	the	HSE	published	new	guidance	on	Naloxone,	recommending	that	every	individual	in	receipt	of
OST	and	in	contact	with	treatment	providers	should	be	offered	and	encouraged	to	take	a	supply	of	Naloxone.
Before	COVID-19,	all	of	these	policy	choices	were	limited	by	regulatory	obstacles	and	uncertain	political	will.	The
response	to	the	pandemic	has	demonstrated	some	of	the	unnecessary	obstacles	placed	ahead	of	potentially
lifesaving	treatments.	Furthermore,	it	has	only	served	to	reiterate	the	value	and	logic	of	harm	reduction-based	drug
policies.
Why	did	these	barriers	exist	prior	to	the	crisis?	The	epidemic	created	an	overwhelming	public	health	argument	for
the	facilitation	of	immediate	access	to	OST	and	Naloxone.	However,	there	was	already	a	strong	public	health
argument	for	having	no	waiting	lists	for	OST	and	improved	Naloxone	distribution	to	people	who	use	drugs.
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In	Irish	medicine,	the	COVID-19	crisis	facilitated	a	number	of	practice	changes	that	had	persuasive	arguments	in
their	favour	prior	to	COVID-19	(e.g.	emailed	prescriptions,	electronic	social	welfare	certificates,	teleconsultations
etc.)	Why	it	took	a	pandemic	to	overcome	barriers	to	seemingly	obvious	practice	reforms	is	difficult	to	discern.
Possibilities	include	the	effect	of	the	fear	and	uncertainty	that	was	palpable	as	COVID-19	infection	spread	across
the	nation;	the	unification	of	the	health	service	with	a	clear	single	mission	to	reduce	the	transmission	of	infection;	or
more	controversially,	the	fact	that	the	public	health	arguments	in	favour	of	harm	reduction	related	mainly	to	the
protection	of	people	who	use	drugs,	whereas	the	public	health	arguments	that	arose	during	the	COVID-19	crisis
related	to	protecting	the	public	at	large.
The	COVID-19	crisis	acted	as	a	catalyst	for	changes	in	the	delivery	of	harm
reduction	measures	to	homeless	people	who	use	drugs.	We	recommend	that	practices	continue	to	deliver	on	OST
and	Naloxone	policy	objectives	and	that	policy	makers	review	the	evidence	on	BZD	maintenance	treatment.	We
further	encourage	international	jurisdictions	to	see	if	Dublin’s	experience	holds	any	lessons	relevant	for	their
immediate	efforts	to	reduce	COVID-19	transmission	and	save	lives.	We	view	the	COVID-19	experience	as	a
potentially	important	milestone	in	the	development	of	national	drug	policies.
This	post	represents	the	views	of	the	authors	and	not	those	of	the	COVID-19	blog,	nor	LSE.	It	is	an	edited	extract
from	Saving	Lives	in	the	Time	of	COVID-19:	Case	Study	of	Harm	Reduction,	Homelessness	and	Drug	Use	in
Dublin,	Ireland.
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